interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Elafibranor

Generic competition · all medicines · read 12 November 2026

Is there a generic of Elafibranor, and who makes it?

Elafibranor appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Elafibranor1 dosage-form group in the Orange Book
0generic makers listed
  1. Elafibranor appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Iqirvo. No generic is listed as marketed.

20202025203020352040204501brand 2024data datePatent 11857523 listed to expire 30 March 2037Patent 11850223 listed to expire 30 March 2037Patent 11331292 listed to expire 30 March 2037Patent 11185519 listed to expire 30 March 2037Patent 12310935 listed to expire 30 March 2037Patent 12295928 listed to expire 30 March 2037Patent 12295927 listed to expire 30 March 2037Patent 12233038 listed to expire 30 March 2037Patent 12589086 listed to expire 30 March 2037Patent 12673035 listed to expire 5 March 2044Exclusivity NCE to 10 June 2029Exclusivity ODE-486 to 10 June 2031
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 10 June 2029Exclusivity NCE Iqirvo
  • 10 June 2031Exclusivity ODE-486 Iqirvo
  • 30 March 2037Patent 11857523
  • 30 March 2037Patent 11850223
  • 30 March 2037Patent 11331292
  • 30 March 2037Patent 11185519
  • 30 March 2037Patent 12310935
  • 30 March 2037Patent 12295928
  • 30 March 2037Patent 12295927
  • 30 March 2037Patent 12233038

2 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.